<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute opioid intoxication in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute opioid intoxication in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute opioid intoxication in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Hoffman, MD, FAACT, FEAPCCT, FRCP Edin
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evan Schwarz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 11, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opiates extracted from the poppy plant (Papaver somniferum) have been used recreationally and medicinally for millennia. Opiates belong to the larger class of drugs, the opioids, which include synthetic and semi-synthetic drugs, as well. Opioid abuse is a worldwide problem and deaths from opioid overdose are numerous and increasing [
         <a href="#rid1">
          1-5
         </a>
         ].
        </p>
        <p>
         This topic review will discuss the mechanisms, clinical manifestations, and management of acute opioid toxicity. A summary table to facilitate emergent management is provided  (
         <a class="graphic graphic_table graphicRef55540" href="/z/d/graphic/55540.html" rel="external">
          table 1
         </a>
         ). Issues related to opioid withdrawal, opioid use disorder, and general management of the poisoned patient are found elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHARMACOLOGY AND CELLULAR TOXICOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The opioid pharmaceuticals are analogous to the three families of endogenous opioid peptides: enkephalins, endorphins, and dynorphin. The most recent classification scheme identifies three major classes of opioid receptor, with several minor classes [
         <a href="#rid6">
          6
         </a>
         ]. Within each receptor class there are distinct subtypes. Each subtype produces a variety of distinct clinical effects, although there is some overlap  (
         <a class="graphic graphic_table graphicRef64386" href="/z/d/graphic/64386.html" rel="external">
          table 2
         </a>
         ). For most clinicians, the nomenclature derived from the Greek alphabet is more familiar, although the International Union of Pharmacology (IUPHAR) Committee on Receptor Nomenclature has recommended a change from the original Greek system to make opioid receptor names more consistent with other neurotransmitter systems [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The opioid receptors are distinct in their locations and clinical effects, but they are structurally similar  (
         <a class="graphic graphic_table graphicRef64386" href="/z/d/graphic/64386.html" rel="external">
          table 2
         </a>
         ). Each consists of seven transmembrane segments, with amino acid and carboxy termini. Although the opioid receptors are all coupled to G proteins, they use a variety of signal transduction mechanisms [
         <a href="#rid6">
          6
         </a>
         ]. These include reducing the capacity of adenylate cyclase to produce cAMP, closing calcium channels that reduce the signal to release neurotransmitters, or opening potassium channels to hyperpolarize the cell [
         <a href="#rid6">
          6
         </a>
         ]. The net result of these mechanisms is to modulate the release of neurotransmitters.
        </p>
        <p>
         Opioid receptors exist throughout the central and peripheral nervous system and are linked to a variety of neurotransmitters, which explains the diversity of their clinical effects. The analgesic effects of opioids result from inhibition of nociceptive information at multiple points of its transmission from the peripheral nerve to the spinal cord to the brain. Euphoria results from increased
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         released in the mesolimbic system [
         <a href="#rid7">
          7
         </a>
         ]. Anxiolysis results from effects on noradrenergic neurons in the locus ceruleus [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         As of 2013, overdoses with synthetic opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         and fentanyl analogs) became increasingly more common [
         <a href="#rid9">
          9
         </a>
         ]. Since 2016, non-fentanyl-related synthetic opioids have entered the illicit drug market. These include benzimidazoles (isotonitazene, etonitazene, metodesnitazene, metonitazene, protonitazene), nortilidine, carbonylbromadol, brorphine, 2-methyl-AP-237, U-47700, and others [
         <a href="#rid10">
          10
         </a>
         ]. The synthetic opioids tend to rapidly enter the central nervous system due to high lipophilicity and are very potent opioid receptor agonists (often similar or more potent compared with fentanyl) [
         <a href="#rid9">
          9,11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          KINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast number of opioids precludes presenting pharmacokinetic data for each one, but a few clinically important generalizations can be made. Most opioids are hepatically metabolized and undergo first-pass metabolism before reaching systemic circulation. The majority of opioids have volumes of distribution of 1 to 10 L/kg, which makes removal of a significant quantity of drug by hemodialysis impossible. They have variable protein binding (from 7.1 percent for
         <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">
          hydrocodone
         </a>
         to 89 percent for
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ) and are renally eliminated. Many opioids are metabolized via phase I metabolism in the liver to active metabolites. As an example, hydrocodone is metabolized to
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         by Cytochrome P450 (CYP) 2D6. CYP polymorphisms cause variations in clinical effect, especially for
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         . A person with limited or slow CYP2D6 function would be less likely to experience the therapeutic effects of codeine, which must be converted to
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         to have an analgesic effect. Phase II metabolism is also important, as exemplified by the metabolism of morphine to morphine-6-glucuronide [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Clinically, the most important pharmacokinetic difference among opioids is the wide variation in serum half-life  (
         <a class="graphic graphic_table graphicRef70480" href="/z/d/graphic/70480.html" rel="external">
          table 3
         </a>
         ). The half-life data in this table, taken from healthy subjects receiving therapeutic doses, should serve only as a rough guide to the duration of clinical effect. Actual effects are influenced by dose, an individual's tolerance, and the presence of active metabolites.
        </p>
        <p>
         In overdose, the apparent half-life may vary significantly from therapeutic dosing. If many tablets are taken, dissolution and absorption will be delayed, prolonging the apparent half-life. Duration of action may also be shortened in overdose. As an example, when a sustained-release formulation of
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         is crushed before ingestion, the drug is rapidly absorbed. While the user's intent is to increase euphoria, the chance of significant morbidity is increased as well.
        </p>
        <p>
         Although active metabolites of some opioids (eg,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ) accumulate in patients with impaired kidney function, such metabolites are not dialyzable and management is unchanged [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES OF OVERDOSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important clinical features related to opioid toxicity are discussed here. A general approach to the overdose patient is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinician should attempt to identify the specific drug, dose, and formulation to which the patient was exposed, the presence of nonopioid co-exposures, and the individual's prior history of opioid use. One review found the "typical" heroin death to involve experienced users in their 20s to 30s using coingestants [
         <a href="#rid14">
          14
         </a>
         ]. In the United States, alcohol and benzodiazepines are common coingestants [
         <a href="#rid15">
          15
         </a>
         ]. Recently released prisoners are at higher risk of opioid overdose in the post-release period because of lost tolerance during incarceration [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
         While not essential for management, historical features help predict the expected duration of poisoning. History should also determine the reason for poisoning, as the patient's intention will influence post-overdose management. Generally, opioid exposures will fall into one of several categories: therapeutic use, recreational use, intended self-harm, attempt to hide drugs from law enforcement out of fear for arrest ("body stuffing"), swallowing large quantities of packaged drugs in order to transport them across borders ("body packing"), and unintentional pediatric exposures.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physical examination helps to: confirm the diagnosis of opioid poisoning; determine the extent of toxicity; identify other conditions requiring treatment; and prevent further exposure  (
         <a class="graphic graphic_table graphicRef77213" href="/z/d/graphic/77213.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         The classic signs of opioid toxicity include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depressed mental status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased respiratory rate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased tidal volume
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased bowel sounds
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miotic (constricted) pupils
        </p>
        <p>
        </p>
        <p>
         Normal pupil examination does
         <strong>
          not
         </strong>
         exclude opioid toxicity. Users of
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         [
         <a href="#rid18">
          18
         </a>
         ] often present with normal pupils, and the presence of coingestants (such as sympathomimetics or anticholinergics) make pupils appear normal or large. The best predictor of opioid toxicity is a respiratory rate &lt;12/minute, which predicted response to
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         in virtually all patients in one series [
         <a href="#rid19">
          19
         </a>
         ]. The clinician should measure the respiratory rate and pay close attention to chest wall excursion, as subtle changes in respiratory effort are often not identified using triage vital signs.
        </p>
        <p>
         While decreased respiratory rate is the most notable vital sign abnormality, heart rate ranges from normal to low, although this is not usually consequential. Mild hypotension (from histamine release) may develop in some patients [
         <a href="#rid20">
          20
         </a>
         ]. Pulse oximetry should be performed in every patient, although the clinician should be wary that mild hypercapnia can be present in the setting of normal oxygen saturation when breathing room air and can be particularly severe when the patient is placed on supplemental oxygen. To monitor end-tidal CO
         <sub>
          2
         </sub>
         (EtCO
         <sub>
          2
         </sub>
         ), and thereby ventilation, directly, clinicians can use capnography. When increased, EtCO
         <sub>
          2
         </sub>
         often predicts respiratory complications, although a normal value does not exclude such problems [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/273.html" rel="external">
          "Carbon dioxide monitoring (capnography)"
         </a>
         .)
        </p>
        <p>
         Obtain a core temperature from any patient with more than minimal symptoms. Hypothermia, which results from a combination of environmental exposure and impaired thermogenesis, should be identified and treated. In a severely obtunded patient, even room temperature can produce significant hypothermia. Elevated temperature suggests early aspiration pneumonia or complications of injection drug use, such as endocarditis.
        </p>
        <p>
         Mental status can range from euphoria to coma, or be nearly normal. Seizures typically occur in the setting of
         <a class="drug drug_general" data-topicid="9511" href="/z/d/drug information/9511.html" rel="external">
          tapentadol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         overdose, or as a result of hypoxia from any opioid.
        </p>
        <p>
         During the secondary survey, look for signs of trauma, particularly to the head. Not only do opioids predispose the patient to trauma, but obtundation from traumatic brain injury can be misidentified as drug toxicity. Pulmonary findings such as crackles indicate the presence of aspiration or acute respiratory distress syndrome. If the patient is suspected of attempting to hide drugs out of fear for arrest, rectal and vaginal examination should be performed, but only with the patient's permission if they are conscious. If the patient cannot give consent because of poisoning, consent is inferred based on medical necessity. Examination is performed for diagnosis and clinical care and not for evidence collection for law enforcement. Examination of the skin may identify medication patches that must be removed, track marks suggesting history of chronic injection drug use, or coexisting soft tissue infections  (
         <a class="graphic graphic_picture graphicRef86745" href="/z/d/graphic/86745.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Toxicities of specific opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the general features described above, some opioids have specific toxicities. A brief description of the notable, albeit infrequent, effects and characteristics of several opioids commonly encountered in the overdose patient follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Buprenorphine – Partial opioid agonist; induces withdrawal in opioid-dependent patients who have full agonists in their system
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dextromethorphan – Serotonin toxicity; at high doses exhibits some µ effects of opioids (miosis, respiratory and CNS depression) but is not a pure opioid agonist
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fentanyl – Very short acting; may be associated with an acute amnestic syndrome in overdose [
         <a href="#rid22">
          22
         </a>
         ] and chest wall rigidity even at therapeutic doses
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrocodone – Often combined with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loperamide – QRS and QT interval prolongation; wide-complex tachycardia; loses specificity for gastrointestinal tract in overdose [
         <a href="#rid23">
          23-28
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meperidine – Seizure, serotonin toxicity (in combination with other agents) (see
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methadone – Very long-acting; QT interval prolongation, Torsade de Pointes (see
         <a class="local">
          'Electrocardiography'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxycodone – Often combined with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ; possible QT interval prolongation [
         <a href="#rid29">
          29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tramadol and tapentadol – Seizure, serotonin toxicity (see
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of opioid toxicity includes toxic and nontoxic conditions.
        </p>
        <p>
         There are myriad drugs that produce coma  (
         <a class="graphic graphic_table graphicRef59515" href="/z/d/graphic/59515.html" rel="external">
          table 5
         </a>
         ). Ethanol, alpha-2 receptor agonists (eg,
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , xylazine), and sedative-hypnotics (eg, benzodiazepines,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ],
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ) may be the most clinically-relevant drugs in the differential diagnosis, because they are frequent intoxicants. While clonidine produces miosis and obtundation, bradycardia, and hypotension are more prominent. Ethanol intoxication produces little to no miosis and no change in bowel sounds. The sedative-hypnotics result in less respiratory depression than the opioids, especially when taken orally. (See
         <a class="medical medical_review" href="/z/d/html/333.html" rel="external">
          "Ethanol intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6509.html" rel="external">
          "Clonidine, xylazine, and related imidazoline poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139762.html" rel="external">
          "Gabapentinoid poisoning and withdrawal"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141081.html" rel="external">
          "GABA-B agonist (baclofen, phenibut) poisoning and withdrawal"
         </a>
         .)
        </p>
        <p>
         The presence of coingestants often confounds the diagnosis of opioid toxicity. While it is frequently impossible to determine the exact substances to which the patient was exposed, a careful history, physical examination, and judicious use of laboratory studies will determine the correct course of management. The sine qua non of opioid toxicity is a clinical response to an antagonist, although giving large doses of antagonist to establish the diagnosis of opioid toxicity is usually not helpful and potentially dangerous, and therefore not recommended. (See
         <a class="local">
          'Management'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p>
         Any medical condition that produces coma may be mistaken for (or occur in conjunction with) opioid toxicity. The most important conditions to exclude are those in which a delay to diagnosis will delay definitive care, such as stroke, electrolyte abnormality, and sepsis  (
         <a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">
          "Stupor and coma in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          LABORATORY EVALUATION AND ANCILLARY STUDIES
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Laboratory evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rapid serum glucose concentration should be obtained in all suspected cases of opioid toxicity. Hypoglycemia is prevalent, easily detectable, rapidly correctable, and potentially confused with opioid toxicity. Most patients with mild or moderate unintentional or recreational toxicity can be managed successfully without any further laboratory investigation.
        </p>
        <p>
         After any overdose in which the opioid is formulated with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , or any overdose that is the result of intended self-harm, serum acetaminophen concentration should be obtained. In one series, 1 in 365 individuals with suicidal ingestion and history negative for acetaminophen ingestion had a potentially hepatotoxic acetaminophen concentration [
         <a href="#rid31">
          31
         </a>
         ]. It is not essential to obtain a salicylate concentration in the absence of clinical suspicion or signs of overdose (eg, tachypnea or increased anion gap). (See
         <a class="medical medical_review" href="/z/d/html/318.html" rel="external">
          "Acetaminophen (paracetamol) poisoning: Management in adults and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/329.html" rel="external">
          "Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p>
         To exclude rhabdomyolysis in the patient presenting after prolonged immobilization, serum creatine phosphokinase concentration should be obtained. Further testing, such as serum creatinine and electrolytes, may be needed depending on clinical circumstances. (See
         <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">
          "Rhabdomyolysis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14034.html" rel="external">
          "Clinical features and diagnosis of heme pigment-induced acute kidney injury", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Urine toxicologic screens should
         <strong>
          not
         </strong>
         be routinely obtained. Acute opioid toxicity is a clinical diagnosis; the management of a patient with an opioid toxidrome is unchanged by the result of a urine opioid screen. A positive test indicates recent use but does not confirm acute toxicity and may even represent a false positive. Conversely, many opioids, especially the synthetic drugs, will produce false-negative results in many urine screens. Commonly available laboratory assays (eg, for
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ) can be performed if the history or examination suggests coingestion. (See
         <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">
          "Testing for drugs of abuse (DOAs)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Electrocardiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         An electrocardiogram (ECG) should be obtained when the patient is suspected of intended self-harm or a coexposure likely to cause cardiovascular complications is possible (eg, cocaine or a cyclic antidepressant). With a few exceptions, electrocardiography can be omitted in other types of opioid exposure.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          Loperamide
         </a>
         is associated with cardiac conduction disturbances ranging in severity from QRS widening to QT interval prolongation, ventricular tachycardia (polymorphic and monomorphic), and idioventricular rhythm [
         <a href="#rid32">
          32
         </a>
         ].
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          Methadone
         </a>
         also increases the QT interval and can cause Torsade de Pointes. This phenomenon more commonly occurs in patients taking high daily doses of the drug [
         <a href="#rid33">
          33
         </a>
         ]. However, the observations that most people who take very large doses of methadone tolerate it well and that some have developed QT interval prolongation from lower doses suggest individual susceptibility to the condition varies. There may also be an association with
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         toxicity and QT interval prolongation [
         <a href="#rid29">
          29,34
         </a>
         ]. (See
         <a class="local">
          'Treatment of toxicity of specific opioids'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
         The benefit of performing an ECG on every individual with a history of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         exposure is unstudied and cannot be recommended. Rather, the test should generally be reserved for those patients presenting after a large dose increase or with complaints suggesting a dysrhythmia, such as palpitations or syncope.
        </p>
        <p>
         If QRS or QT interval prolongation is identified on the initial ECG, continuous cardiac monitoring including serial ECGs should be continued until intervals normalize or return to baseline. If the initial ECG is normal, it is reasonable to repeat the test in four to six hours if there is suspicion of a large exposure.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiography is reserved for those patients with adventitious lung sounds or hypoxia that does not correct when hypoventilation is addressed. Abnormal lung sounds suggest aspiration pneumonia or acute respiratory distress syndrome. (See
         <a class="local">
          'Lung injury and ARDS'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"
         </a>
         .)
        </p>
        <p>
         Imaging of drug packets is discussed below. (See
         <a class="local">
          'Body packing and body stuffing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Basic measures and antidotal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         General management of the overdose patient is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .) Specific management strategies for opioid toxicity are discussed below. A summary table to facilitate emergent management is provided  (
         <a class="graphic graphic_table graphicRef55540" href="/z/d/graphic/55540.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basic measures
         </strong>
         – Once opioid toxicity is suspected, initial management should focus on support of the patient's airway and breathing. Attention should be paid to the depth and rate of ventilation. While pulse-oximetry is useful for monitoring oxygenation, it is not useful for gauging ventilation when supplemental oxygen is being given. Capnography can be used to monitor patient ventilation. The presence of elevated end tidal CO
         <sub>
          2
         </sub>
         (EtCO
         <sub>
          2
         </sub>
         ) in opioid-toxic patients may predict complications, although its absence cannot exclude them. In a prospective cohort study of 201 patients poisoned with respiratory depressants, noninvasive end tidal EtCO
         <sub>
          2
         </sub>
         &gt;50 mmHg predicted complications of hypoventilation with 46 percent sensitivity and 86 percent specificity [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/273.html" rel="external">
          "Carbon dioxide monitoring (capnography)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antidotal therapy with
         </strong>
         <strong>
          naloxone
         </strong>
         – Administer
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , a short-acting opioid antagonist, preferably by the intravenous (IV) route.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing in a patient with apnea or impending respiratory arrest
         </strong>
         – Apneic patients should receive higher initial doses of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         (0.2 to 1 mg). Patients in cardiorespiratory arrest following possible opioid overdose should be given a minimum of 2 mg of naloxone [
         <a href="#rid35">
          35,36
         </a>
         ]. The apneic patient and patients with extremely low respiratory rates or shallow respirations should be ventilated by bag-valve mask attached to supplemental oxygen prior to and during naloxone administration to reduce the chance of acute respiratory distress syndrome [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/267.html" rel="external">
          "Basic airway management in adults"
         </a>
         and
         <a class="local">
          'Lung injury and ARDS'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing in a patient with spontaneous ventilation
         </strong>
         – When spontaneous ventilations are present, an initial dose of 0.04 or 0.05 mg intravenously is an appropriate starting point, and the dose should be titrated upward every few minutes until the respiratory rate is 12 breaths per minute or greater [
         <a href="#rid38">
          38,39
         </a>
         ]. A common approach is to dilute 1 mL of a
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         0.4 mg/mL formulation with 9 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or sterile water for injection (creating a total volume of 10 mL with a 0.04 mg/mL concentration) and administering 1 to 2 mL aliquots. The goal of naloxone administration is
         <strong>
          not
         </strong>
         a normal level of consciousness, but adequate ventilation. In the absence of signs of opioid withdrawal, there is no maximum safe dose of naloxone. However, if a clinical effect does not occur after 5 to 10 mg, the diagnosis should be reconsidered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administering in a patient without IV access
         </strong>
         –
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          Naloxone
         </a>
         may be given nasally, subcutaneously, intramuscularly, or intraosseously if there is a delay in securing IV access. When given by these routes, there is slower absorption and delayed elimination, making the drug much more difficult to titrate. Naloxone is also absorbed in the respiratory tract, and thus, can be administered into an endotracheal tube or nebulized. Conceptually, there is little role for nebulized or nasal naloxone in the hospital setting because the dose administered is determined by the patient's ventilation, thus the most severely poisoned patients will absorb the least amount of antidote [
         <a href="#rid40">
          40
         </a>
         ]. The respiratory route and other routes of administration are less predictable. In addition, IV access is required in these patients as other medications (such as hypertonic dextrose) may be needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administering
         </strong>
         <strong>
          naloxone
         </strong>
         <strong>
          infusion
         </strong>
         – After ventilation is restored with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , repeat doses may be required, depending on the quantity and duration of action of the opioid. As an alternative to repeat dosing, a naloxone infusion can be prepared by determining the total initial dose required to reinstate breathing and delivering two-thirds of that dose every hour [
         <a href="#rid41">
          41
         </a>
         ]. If the patient develops withdrawal signs or symptoms during the infusion, stop the infusion. If toxicity returns, restart the infusion at half the initial rate. If the patient develops respiratory depression during the infusion, readminister half the initial bolus every few minutes until symptoms improve, then increase the infusion by half the initial rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of precipitated withdrawal from
         </strong>
         <strong>
          naloxone
         </strong>
         <strong>
          administration
         </strong>
         – If the clinician "overshoots" the appropriate dose of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         in a patient with opioid use disorder, withdrawal will ensue. Symptoms of withdrawal should be managed expectantly only,
         <strong>
          not
         </strong>
         with additional opioids. To overcome naloxone antagonism requires a large dose of opioids. More importantly, because naloxone has a short duration of action, any opioid administered will result in even more toxicity once the effects of naloxone subside. (See
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other opioid antagonists
         </strong>
         –
         <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">
          Nalmefene
         </a>
         nasal spray was approved in the United States for acute opioid intoxication in adults and adolescents in 2023 (parenteral nalmefene was previously approved for use in adults). We recommend against routine clinical use of nalmefene (intranasal or parenteral) in adults given the extensive clinical experience with intranasal
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , lack of comparative trials, and concern for precipitating prolonged withdrawal [
         <a href="#rid42">
          42
         </a>
         ]. According to the manufacturer’s pharmacokinetic and pharmacodynamic modeling data, following intranasal 2.7 mg administration, nalmefene would be expected to maintain a 50 percent effective concentration for almost six hours [
         <a href="#rid43">
          43
         </a>
         ]. By comparison, intranasal administration of naloxone 2.8 mg maintains an effective concentration comparable at three hours to concentrations achieved by a 0.4 mg dose of IV naloxone at one hour [
         <a href="#rid44">
          44
         </a>
         ]. Since intranasal naloxone doses of 4 mg or greater are typically used, the duration of efficacy following routine administration is expected to be longer than three hours, thus obviating the utility of a longer-acting antagonist such as nalmefene.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Gastrointestinal decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Activated charcoal and gastric emptying are almost never indicated in opioid toxicity. Gastrointestinal decontamination has some risk and opioid toxicity is readily treatable by other means. While orogastric lavage could remove tablets still in the stomach, and activated charcoal binds opioids, each of these therapies produces a risk of aspiration, especially in the obtunded, opioid-poisoned patient. Gastrointestinal decontamination should be reserved for patients presenting with potentially life-threatening coingestants, not for opioids alone, and should be performed only if the airway is secure. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Extracorporeal removal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The large volume of distribution of the opioids precludes removal of a significant quantity of drug by hemodialysis.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Body packing and body stuffing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Body packing is described as the act of swallowing packets or containers of drug for the purposes of smuggling. Body packers are generally participants in international drug networks who are transporting massive amounts of well-packaged drugs across international borders. Heroin and cocaine are more frequently implicated than other drugs. "Body stuffing" refers to the swallowing of a smaller quantity of drug because of fear of arrest. Compared with body packers, body stuffers typically carry a far smaller quantity of drug, but the drug is more poorly packaged.
        </p>
        <p>
         In many cases, body packers or stuffers are identified by law enforcement officials and referred to clinicians for evaluation, but a substantial number of body packers present to physicians with symptoms either related to intestinal obstruction or drug toxicity. Recognition of body packing is accomplished through the history, examination findings, and diagnostic imaging. Severe toxicity from leaking packages or large ingestions poses a major threat to these patients and aggressive interventions may be needed. Large amounts of heroin or other opioids may be released from a leaking package, requiring extremely high doses of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . The presentation, diagnosis, and management of body packers and body stuffers is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/327.html" rel="external">
          "Internal concealment of drugs of abuse (body packing)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13845.html" rel="external">
          "Acute ingestion of illicit drugs (body stuffing)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Lung injury and ARDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute respiratory distress syndrome (ARDS) is a potential adverse effect of all opioids [
         <a href="#rid45">
          45-47
         </a>
         ]. The signs, which typically include crackles, hypoxia, and occasionally frothy sputum, often occur as a patient is recovering from opioid-induced respiratory depression. The pathophysiology is unclear, but in some cases ARDS occurs in the setting of iatrogenic reversal of opioid toxicity (such as with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         ). In such cases, rapid precipitation of withdrawal in the setting of elevated PCO
         <sub>
          2
         </sub>
         is associated with a surge in catecholamine concentrations, thereby increasing afterload, which causes interstitial edema followed by alveolar filling [
         <a href="#rid37">
          37
         </a>
         ]. Because of this, very small doses of naloxone (0.04 to 0.05 mg to start) should be used on those patients with marked hypoventilation and they should be ventilated with a bag-valve mask prior to administration of naloxone. (See
         <a class="local">
          'Basic measures and antidotal therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/267.html" rel="external">
          "Basic airway management in adults"
         </a>
         .)
        </p>
        <p>
         Management of opioid and naloxone-related ARDS is supportive and the prognosis is generally good if it is identified and addressed promptly. The clinical manifestations and management of ARDS are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">
          "Acute respiratory distress syndrome: Ventilator management strategies for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">
          "Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          TREATMENT OF TOXICITY OF SPECIFIC OPIOIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several opioids possess uncommon toxicities that may require specific interventions.
        </p>
        <p class="headingAnchor" id="H2282453505">
         <span class="h2">
          Loperamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         In extreme overdose (doses many times those used for antidiarrheal treatment – typically 30 to 40 pills or more),
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         can cause ventricular conduction disturbances including QRS and QT interval prolongation, idioventricular rhythm, and ventricular tachycardia (monomorphic and polymorphic) [
         <a href="#rid48">
          48,49
         </a>
         ].
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          Sodium bicarbonate
         </a>
         is recommended for management of other drug-induced sodium channel toxicity [
         <a href="#rid50">
          50
         </a>
         ]. The clinical benefit of this intervention is unknown, but if QRS prolongation is encountered, we recommend administering a bolus of 1 to 2 mEq/kg of sodium bicarbonate intravenously in the absence of contraindications. If the complex narrows, a bicarbonate infusion is reasonable. We mix 132 mEq of NaHCO
         <sub>
          3
         </sub>
         in one liter of D
         <sub>
          5
         </sub>
         W, and infuse at 250 mL/hour. Since loperamide also causes QT interval prolongation, it is important to monitor potassium and magnesium if bicarbonate is given, as depletion will increase the risk for QT interval prolongation. Cardiac toxicity may persist for several days, requiring admission, ongoing cardiac monitoring, and treatment as indicated.
        </p>
        <p>
         The management of patients with acquired QT prolongation or Torsade de Pointes is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management", section on 'Initial management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H790633510">
         <span class="h2">
          Methadone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          Methadone
         </a>
         can cause QT interval prolongation and Torsade de Pointes. If the QT is determined to be greater than 500 msec [
         <a href="#rid51">
          51
         </a>
         ], we recommend that the patient be observed on a cardiac monitor for a 24-hour period. Hypocalcemia, hypokalemia, and hypomagnesemia should be corrected when present [
         <a href="#rid52">
          52
         </a>
         ]. The clinician should either stop methadone therapy, or switch to
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         , if the patient's psychosocial situation permits this. (See
         <a class="local">
          'Electrocardiography'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3593343135">
         <span class="h2">
          Fentanyl and fentanyl analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          Fentanyl
         </a>
         and fentanyl analogs (commonly called "fentalogs") are increasingly entering the drug supply as counterfeit tablets [
         <a href="#rid53">
          53-55
         </a>
         ] or substituted for heroin [
         <a href="#rid56">
          56
         </a>
         ]. These analogs include drugs such as
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         , and
         <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">
          sufentanil
         </a>
         , as well as drugs that are not approved for use in humans, such as carfentanil, furanylfentanyl, and others. Fentanyl is 50 to 100 times more potent than
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         and some analogs are even stronger. Despite anecdotal reports of a higher
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         requirements for treatment, standard doses of naloxone should be sufficient to restore ventilation. (See
         <a class="local">
          'Basic measures and antidotal therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H29872809">
         <span class="h2">
          Buprenorphine and naloxone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         is a partial agonist at the opioid receptor. When taken alone, buprenorphine can cause respiratory depression, but likely to a limited degree. Although most fatalities associated with buprenorphine have occurred in the setting of mixed overdose where the coingestant produced or contributed to respiratory depression (eg, alcohol or benzodiazepines), fatalities have occurred from buprenorphine toxicity alone [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         binds to the opioid receptor with high affinity. In experimental models, high doses of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         were needed to reverse respiratory depression. Interestingly, because of complex physiology, respiratory depression can recur with very high doses of naloxone. This effect is described as a "bell-shaped" dose-response curve and may be a result of the high affinity of buprenorphine for the opioid receptor compared to naloxone [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Such research has led some to conclude that respiratory depression from
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         may be difficult to reverse with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . In observational studies of buprenorphine toxicity, the response to naloxone is mixed. In a case series of patients with buprenorphine or
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         overdose, none of the 19 patients administered 0.4 to 0.8 mg of naloxone had an adequate response [
         <a href="#rid59">
          59
         </a>
         ]. In contrast, standard naloxone doses were adequate for reversal of buprenorphine effects in a small series of pediatric patients treated in an intensive care unit for buprenorphine toxicity [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         In the adult patient with buprenorphine-associated respiratory depression, start with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         0.4 to 0.8 mg intravenously (IV) but be prepared to titrate to higher doses (single doses of up to 2 mg, for a total of 10 mg) than are typically required to treat respiratory depression from other opioids. It is unlikely that an adult patient develops significant respiratory depression from
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         alone; thus, evaluate for co-ingestants that can synergistically contribute to respiratory depression. After initial reversal is achieved, a naloxone infusion is often preferable to serial boluses. Infusion dosing is described above. (See
         <a class="local">
          'Basic measures and antidotal therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3565043708">
         <span class="h2">
          Benzimidazoles and brorphine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benzimidazoles (isotonitazene, etonitazene, N-piperidinyl etonitazene, metodesnitazene, metonitazene, protonitazene) are synthetic opioid agonists with structures distinct from
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         or
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         . These drugs generally have potencies at opioid receptors similar to, or exceeding, fentanyl. Since 2019, the benzimidazoles are increasingly implicated in overdoses [
         <a href="#rid9">
          9,11,61
         </a>
         ].
        </p>
        <p>
         Brorphine is an opioid-agonist with structural similarities to both benzimidazoles and
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         . Brorphine was synthesized in 2018 as a novel opioid with high G protein signaling bias (and theoretically less respiratory depression) and was identified in the United States illicit opioid market one year later [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p>
         Isotonitazene, brorphine, and other novel opioids have followed a pattern of emergence and disappearance from the worldwide illicit drug supply [
         <a href="#rid10">
          10,64,65
         </a>
         ]. We expect this pattern to continue with emerging novel opioids. The declines occurred after legislative measures (eg, drug scheduling) were enacted in response to drug discovery in illicit markets. As of 2021, metonitazene and other benzimidazoles continue to be found in the United States illicit drug supply [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         We do not expect emerging novel opioids to be detected with standard hospital immunoassay drug screens because they are structurally distinct from
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">
          "Testing for drugs of abuse (DOAs)", section on 'Opioids'
         </a>
         .)
        </p>
        <p>
         Regardless, management principles remain unchanged. Opioid toxicity from isotonitazene overdose will respond to
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , but the need for higher doses and repeat administration has been reported by some authors [
         <a href="#rid64">
          64,66
         </a>
         ], but not all [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="local">
          'Basic measures and antidotal therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2271894777">
         <span class="h2">
          Opioid adulterants, including krokodil
         </span>
         <span class="headingEndMark">
          —
         </span>
         Illicitly purchased drugs frequently contain adulterants, some of which may cause clinical problems distinct from the desired compound. From the perspective of the drug seller, the ideal adulterant would be inexpensive, appear and taste similar to the desired drug, and not harm the user. Nonetheless, opioids containing harmful adulterants are common, and examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Krokodil" (from the Russian word for crocodile) is a homemade formulation of the potent, short-acting opioid desomorphine [
         <a href="#rid68">
          68,69
         </a>
         ]. Derived from
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         , which is available without prescription in Russia, krokodil is reported to contain solvents, such as gasoline and lighter fluid. Other potential contaminants include iodine, hydrochloric acid, and red phosphorous. Subcutaneous injection has resulted in local tissue damage, including ulcers, skin necrosis, and infection. The name of the drug is derived from the scaly skin lesions observed in some users. Such lesions are likely the result of infection and/or direct tissue injury from adulterants, as desomorphine itself would not be expected to cause tissue toxicity, and similar findings were commonly seen with subcutaneous injection of impure heroin in the 1980's in the United States. Although there is an epidemic of cases of tissue damage from krokodil injection in former Soviet republics, cases outside this region remain uncommon [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alkaloids, such as
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         and strychnine, are harmful adulterants that have been implicated in heroin-related deaths [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/310.html" rel="external">
          "Strychnine poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heroin has also been tainted with the anticholinergic
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         and the beta-adrenergic agonist clenbuterol, both of which have caused widespread toxicity [
         <a href="#rid71">
          71,72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Xylazine, an alpha-2 adrenergic receptor agonist used as a veterinary sedative that is increasingly being found in illicit heroin and
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , causes clinical toxicity similar to opioids, and with repeat injection can lead to severe, necrotic skin ulcerations. (See
         <a class="medical medical_review" href="/z/d/html/6509.html" rel="external">
          "Clonidine, xylazine, and related imidazoline poisoning", section on 'Xylazine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the exception of overdoses involving long-acting opioids such as
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         , most adult patients with opioid toxicity can be managed in the emergency department (ED) without need for hospital admission, assuming there is no other medical issue of sufficient concern. Generally, the patient may be discharged or transferred for psychiatric evaluation once respiration and mental status are normal and
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         has not been administered for two to three hours. Although the half-life of naloxone is just over one hour, its duration of effect is shorter. Therefore, following
         <strong>
          injection
         </strong>
         opioid use, a two- to three-hour period of observation is generally sufficient. However, in the case of a large
         <strong>
          ingestion
         </strong>
         , the clinician should consider the possibility of late absorption of drug (even if the drug is short acting), and a longer period of observation may be needed [
         <a href="#rid73">
          73-76
         </a>
         ].
        </p>
        <p>
         A longer period of observation is also recommended for patients who have been reversed with large doses (2 to 4 mg) of intranasal
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . Because of the dose administered and slow absorption, high-dose intranasal naloxone can result in "therapeutic" naloxone concentrations for three hours or even longer [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Management of opioid toxicity in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">
          "Opioid intoxication in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10057659">
         <span class="h1">
          PREVENTION OF RECURRENT OPIOID OVERDOSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who present to the emergency department (ED) surviving an opioid overdose, the one-year mortality rate is 5.5 percent; 20 percent of those patients die in the first month after the index ED visit [
         <a href="#rid77">
          77
         </a>
         ]. In individuals who have survived an opioid overdose, initiation of opioid agonist therapy is associated with decreased all-cause and opioid-related mortality compared with no medication treatment [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ED initiation of medications for opioid use disorder (MOUD)
         </strong>
         – ED initiation of MOUD is feasible and cost effective [
         <a href="#rid79">
          79,80
         </a>
         ]. When ED-initiated
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         was compared with a brief psychosocial intervention and referral, patients who received buprenorphine were significantly more engaged in substance use disorder treatment, reduced self-reported illicit opioid use, and decreased use of inpatient addiction treatment services [
         <a href="#rid79">
          79
         </a>
         ]. Many United States EDs have successfully implemented similar programs despite multiple barriers, such as the previously required federal "X-waiver" for buprenorphine prescribing [
         <a href="#rid81">
          81
         </a>
         ]. In January 2023, the federal X-waiver requirement was removed, allowing clinicians with schedule III authority on their Drug Enforcement Administration (DEA) registration to prescribe buprenorphine for OUD if permitted by applicable state law [
         <a href="#rid82">
          82
         </a>
         ]. Similarly, EDs that made systematic efforts to implement and maintain MOUD-initiation programs were able to increase rates of buprenorphine prescribing [
         <a href="#rid83">
          83-85
         </a>
         ]. In contrast, the publication of Canadian clinical practice guidelines in 2018 did not improve MOUD-initiation rates following ED visits for opioid toxicity in Ontario [
         <a href="#rid86">
          86
         </a>
         ], suggesting strategies that directly engage clinicians are more likely to be successful. Because at-home buprenorphine induction strategies are safe and effective, patients do not have to wait in the ED to develop opioid withdrawal prior to initiation of therapy [
         <a href="#rid87">
          87
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Take-home
         </strong>
         <strong>
          naloxone
         </strong>
         – The use of bystander-administered intranasal
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         to resuscitate opioid overdose patients is well reported [
         <a href="#rid75">
          75,88,89
         </a>
         ]. Providing naloxone and education to patients with OUD, as well as their family members and friends, reduces overdose mortality [
         <a href="#rid90">
          90
         </a>
         ]. In one study, overdose deaths decreased from 46.6 to 29 per 100,000 following implementation of a comprehensive opioid overdose prevention program that included take-home naloxone [
         <a href="#rid91">
          91
         </a>
         ]. By 2018, all states in the United States have enacted naloxone access laws permitting dispensing and administering naloxone without a physician's prescription [
         <a href="#rid92">
          92
         </a>
         ]. In 2023, the US Food and Drug Administration approved naloxone for non-prescription (ie, over-the-counter) use. (See
         <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">
          "Prevention of lethal opioid overdose in the community"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other harm reduction strategies
         </strong>
         – In addition to community
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         and MOUD initiation, harm reduction strategies include peer recovery specialist availability, brief motivational interviews, patient and family education, arranging same-day or next-day appointments at substance use disorder programs, and distributing alcohol swabs, sterile injection equipment, and
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         test strips [
         <a href="#rid93">
          93-95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1997998556">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4033736834">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">
          "Society guideline links: Opioid use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112688.html" rel="external">
          "Society guideline links: Poisoning prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Opioid use disorder (OUD) is a worldwide problem, and deaths from opioid overdose are numerous. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical feature of overdose
         </strong>
         – Opioid intoxication a clinical diagnosis. The classic signs include depressed mental status, decreased respiratory rate, decreased tidal volume, decreased bowel sounds, and miotic pupils  (
         <a class="graphic graphic_table graphicRef77213" href="/z/d/graphic/77213.html" rel="external">
          table 4
         </a>
         ). The best predictor of opioid toxicity is a respiratory rate &lt;12 breaths per minute. Normal pupil examination does
         <strong>
          not
         </strong>
         exclude opioid toxicity. In addition to suppression of respiratory rate, opioid toxicity can be complicated by hypothermia, coma, seizure, head trauma, aspiration pneumonia, and rhabdomyolysis. (See
         <a class="local">
          'Clinical features of overdose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          Loperamide
         </a>
         can cause ventricular conduction disturbances, including prolongation of QRS and QT interval duration, idioventricular rhythm, ventricular tachycardia, and torsade de pointes in overdose.
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          Methadone
         </a>
         can cause QT interval prolongation and torsade de pointes. (See
         <a class="local">
          'Toxicities of specific opioids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Any medical condition that produces coma may be mistaken for (or occur in conjunction with) opioid toxicity. The most important conditions to exclude are those in which delay of diagnosis will delay definitive care, such as intracranial hemorrhage, electrolyte abnormality, and sepsis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory investigations
         </strong>
         – A rapid serum glucose concentration should be obtained in all suspected cases of opioid toxicity. Most patients with mild or moderate unintentional poisoning can be managed successfully without any further laboratory investigation. Urine toxicologic screens should
         <strong>
          not
         </strong>
         be routinely obtained since these screens do not change the management of a patient with an opioid overdose, a positive test indicates recent use but does not confirm active toxicity, and many synthetic opioids will produce false-negative results. (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management starts with support of the patient's airway and breathing. Bag-mask ventilation should be performed prior to and during administration of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         in apneic patients and patients with very low respiratory rates. Activated charcoal and gastric emptying are almost never indicated in opioid poisoning. (See
         <a class="local">
          'Basic measures and antidotal therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In cases of suspected opioid toxicity, we recommend treatment with the short-acting opioid antagonist
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). While the intravenous (IV) route is preferred, naloxone may be given intranasally, subcutaneously, or intramuscularly if IV access is unavailable. If a clinical effect does not occur after 5 to 10 mg, the diagnosis should be reconsidered. (See
         <a class="local">
          'Basic measures and antidotal therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with spontaneous ventilations, an initial
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         dose of 0.04 to 0.05 mg is an appropriate starting point, and the dose should be titrated upward every few minutes until the patient is able to maintain a room air oxygen saturation above 90 percent without supplemental oxygen. May dilute 1 mL of a naloxone 0.4 mg/mL formulation with 9 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or sterile water for injection (creating a total volume of 10 mL with a 0.04 mg/mL concentration) and administer 1 to 2 mL aliquots.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          Naloxone
         </a>
         should be titrated to a goal of adequate ventilation instead of a normal level of consciousness since "overshooting" in an opioid-dependent individual will cause withdrawal.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In apneic patients, start with a higher initial dose of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         (0.2 to 1 mg).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients in cardiac arrest should receive a dose no less than 2 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of recurrent opioid overdose
         </strong>
         – The one-year mortality in an emergency department (ED) patient who survives an opioid overdose is 5.5 percent. Initiation of opioid agonist therapy (eg,
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ) is associated with decreased all-cause and opioid-related mortality and is feasible and cost effective. Other harm reduction strategies include take-home
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , peer recovery specialist availability, arranging urgent appointments at substance use disorder programs, and distributing sterile injection equipment. (See
         <a class="local">
          'Prevention of recurrent opioid overdose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disposition
         </strong>
         – In most cases, the patient may be discharged or transferred for psychiatric evaluation once respiration and mental status are normal and
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         administration has not been necessary for two to three hours. (See
         <a class="local">
          'Disposition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H292645497">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Stephen J Traub, MD, former section editor of the toxicology program, for 20 years of dedicated service.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23:589.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings Office of Applied Studies, NSDUH Series H-28, DHHS Publication No. SMA 05-4062, Rockville, MD 2005.
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-28, DHHS Publication No. (SMA) 06-4143, Rockville, MD 2006.
         </li>
         <li class="breakAll">
          QuickStats: Number of Deaths From Poisoning,* Drug Poisoning,† and Drug Poisoning Involving Opioid Analgesics§ — United States, 1999–2010 www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a7.htm?s_cid=mm6212a7_e (Accessed on April 08, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonci A, Bernardi G, Grillner P, Mercuri NB. The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 2003; 24:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aghajanian GK, Wang YY. Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology 1987; 26:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther 2022; 233:108019.
          </a>
         </li>
         <li class="breakAll">
          European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (December 2020). Publications Office of the European Union, Luxembourg, 2020. https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf (Accessed on March 01, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edinoff AN, Martinez Garza D, Vining SP, et al. New Synthetic Opioids: Clinical Considerations and Dangers. Pain Ther 2023; 12:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996; 91:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tori ME, Larochelle MR, Naimi TS. Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017. JAMA Netw Open 2020; 3:e202361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013; 159:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leach D, Oliver P. Drug-related death following release from prison: a brief review of the literature with recommendations for practice. Curr Drug Abuse Rev 2011; 4:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghoneim MM, Dhanaraj J, Choi WW. Comparison of four opioid analgesics as supplements to nitrous oxide anesthesia. Anesth Analg 1984; 63:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med 1991; 20:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahmy NR, Sunder N, Soter NA. Role of histamine in the hemodynamic and plasma catecholamine responses to morphine. Clin Pharmacol Ther 1983; 33:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viglino D, Bourez D, Collomb-Muret R, et al. Noninvasive End Tidal CO2 Is Unhelpful in the Prediction of Complications in Deliberate Drug Poisoning. Ann Emerg Med 2016; 68:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barash JA, Ganetsky M, Boyle KL, et al. Acute Amnestic Syndrome Associated with Fentanyl Overdose. N Engl J Med 2018; 378:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggleston W, Nacca N, Marraffa JM. Loperamide toxicokinetics: serum concentrations in the overdose setting. Clin Toxicol (Phila) 2015; 53:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinner HL, Lonardo NW, Mulamalla R, Stehlik J. Ventricular tachycardia associated with high-dose chronic loperamide use. Pharmacotherapy 2015; 35:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wightman RS, Hoffman RS, Howland MA, et al. Not your regular high: cardiac dysrhythmias caused by loperamide. Clin Toxicol (Phila) 2016; 54:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic Trends in Loperamide Abuse and Misuse. Ann Emerg Med 2017; 69:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggleston W, Clark KH, Marraffa JM. Loperamide Abuse Associated With Cardiac Dysrhythmia and Death. Ann Emerg Med 2017; 69:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borron SW, Watts SH, Tull J, et al. Intentional Misuse and Abuse of Loperamide: A New Look at a Drug with "Low Abuse Potential". J Emerg Med 2017; 53:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manini AF, Stimmel B, Vlahov D. Racial susceptibility for QT prolongation in acute drug overdoses. J Electrocardiol 2014; 47:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattson CL, Chowdhury F, Gilson TP. Notes from the Field: Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths - 23 States and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep 2022; 71:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashbourne JF, Olson KR, Khayam-Bashi H. Value of rapid screening for acetaminophen in all patients with intentional drug overdose. Ann Emerg Med 1989; 18:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marraffa JM, Holland MG, Sullivan RW, et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol (Phila) 2014; 52:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM 2013; 106:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlot G, Gullo A, Romano E, Rinaldi A. Naloxone in cardiorespiratory arrest. Anaesthesia 1985; 40:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertini G, Russo L, Cricelli F, et al. Role of a prehospital medical system in reducing heroin-related deaths. Crit Care Med 1992; 20:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills CA, Flacke JW, Flacke WE, et al. Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J Anaesth 1990; 37:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterwalder JJ. Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol 1996; 34:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Purssell R, Godwin J, Moe J, et al. Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. Clin Toxicol (Phila) 2021; 59:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowling J, Isbister GK, Kirkpatrick CM, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008; 30:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986; 15:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunzler NM, Wightman RS, Nelson LS. Opioid Withdrawal Precipitated by Long-Acting Antagonists. J Emerg Med 2020; 58:245.
          </a>
         </li>
         <li class="breakAll">
          OPVEE (nalmefene) nasal spray [prescribing information]. Santa Monica, CA: Opiant Pharmaceuticals; May 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf (Accessed on May 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skulberg AK, Åsberg A, Khiabani HZ, et al. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. Addiction 2019; 114:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duberstein JL, Kaufman DM. A clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema. Am J Med 1971; 51:704.
          </a>
         </li>
         <li class="breakAll">
          Osler W. Oedema of the left lung—morphia poisoning. Montreal General Hospital Reports Clinical and Pathological, vol 1, Dawson Bros Publishers, Montreal 1880. p.291.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frand UI, Shim CS, Williams MH Jr. Methadone-induced pulmonary edema. Ann Intern Med 1972; 76:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz KD, Cannon RD, Cook MD, et al. Loperamide-Induced Torsades de Pointes: A Case Series. J Emerg Med 2017; 53:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggleston W, Palmer R, Dubé PA, et al. Loperamide toxicity: recommendations for patient monitoring and management. Clin Toxicol (Phila) 2020; 58:355.
          </a>
         </li>
         <li class="breakAll">
          Hoffman RS, Howland MA, Lewin NA, Nelson LN. Antidotes in depth: Sodium bicarbonate. In: Goldfrank’s Toxicologic Emergencies, 10th ed, Goldfrank LE, Kirstein MD (Eds), McGraw-Hill, New York 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manini AF, Nair AP, Vedanthan R, et al. Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose. J Am Heart Assoc 2017; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 2007; 100:609.
          </a>
         </li>
         <li class="breakAll">
          Drug Enforcement Agency. DEA Intelligence Brief. Counterfeit Prescription Pills Containing Fentanyls: A Global Threat. 2016. https://www.dea.gov/docs/Counterfeit%20Prescription%20Pills.pdf (Accessed on July 24, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller JM, Stogner JM, Miller BL, Blough S. Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. Drug Alcohol Rev 2018; 37:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edison L, Erickson A, Smith S, et al. Notes from the Field: Counterfeit Percocet-Related Overdose Cluster - Georgia, June 2017. MMWR Morb Mortal Wkly Rep 2017; 66:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladden RM, Martinez P, Seth P. Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014. MMWR Morb Mortal Wkly Rep 2016; 65:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006; 105:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mégarbane B, Buisine A, Jacobs F, et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 2010; 38:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med 2011; 12:e102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calello DP, Aldy K, Jefri M, et al. Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol (Phila) 2022; 60:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy NM, Schmid CL, Ross NC, et al. Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias. J Med Chem 2018; 61:8895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandeputte MM, Krotulski AJ, Papsun DM, et al. The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament. J Anal Toxicol 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Baerdemaeker KSC, Dines AM, Hudson S, et al. Isotonitazene, a novel psychoactive substance opioid, detected in two cases following a local surge in opioid overdoses. QJM 2023; 116:115.
          </a>
         </li>
         <li class="breakAll">
          United States Drug Enforcement Administration. National estimates for the most frequently identified drugs: 2021. https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amaducci A, Aldy K, Campleman SL, et al. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Netw Open 2023; 6:e2331264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White A, Seah V, Brown J, et al. Acute metonitazene poisoning reversed by naloxone. Clin Toxicol (Phila) 2023; 61:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gahr M, Freudenmann RW, Hiemke C, et al. "Krokodil":revival of an old drug with new problems. Subst Use Misuse 2012; 47:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grund JP, Latypov A, Harris M. Breaking worse: the emergence of krokodil and excessive injuries among people who inject drugs in Eurasia. Int J Drug Policy 2013; 24:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helpern M, Rho YM. Deaths from narcotism in New York City. Incidence, circumstances, and postmortem findings. N Y State J Med 1966; 66:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman RS, Kirrane BM, Marcus SM, Clenbuterol Study Investigators. A descriptive study of an outbreak of clenbuterol-containing heroin. Ann Emerg Med 2008; 52:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton RJ, Perrone J, Hoffman R, et al. A descriptive study of an epidemic of poisoning caused by heroin adulterated with scopolamine. J Toxicol Clin Toxicol 2000; 38:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutter ME, Gerona RR, Davis MT, et al. Fatal Fentanyl: One Pill Can Kill. Acad Emerg Med 2017; 24:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heaton JD, Bhandari B, Faryar KA, Huecker MR. Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal. J Emerg Med 2019; 56:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol (Phila) 2017; 55:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheuermeyer FX, DeWitt C, Christenson J, et al. Safety of a Brief Emergency Department Observation Protocol for Patients With Presumed Fentanyl Overdose. Ann Emerg Med 2018; 72:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner SG, Baker O, Bernson D, Schuur JD. One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose. Ann Emerg Med 2020; 75:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med 2018; 169:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 2015; 313:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busch SH, Fiellin DA, Chawarski MC, et al. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction 2017; 112:2002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whiteside LK, D'Onofrio G, Fiellin DA, et al. Models for Implementing Emergency Department-Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers. Ann Emerg Med 2022; 80:410.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse anda Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement (Accessed on February 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowenstein M, Perrone J, Xiong RA, et al. Sustained Implementation of a Multicomponent Strategy to Increase Emergency Department-Initiated Interventions for Opioid Use Disorder. Ann Emerg Med 2022; 79:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Onofrio G, Edelman EJ, Hawk KF, et al. Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. JAMA Netw Open 2023; 6:e235439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormack RP, Rotrosen J, Gauthier P, et al. Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial. Ann Emerg Med 2023; 82:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu T, McCormack D, Juurlink DN, et al. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario. CMAJ 2023; 195:E1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham CO, Giovanniello A, Li X, et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat 2011; 40:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis 2006; 25:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict 1994; 29:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyon S, Aks SE, Schaeffer S. Expanding access to naloxone in the United States. J Med Toxicol 2014; 10:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albert S, Brason FW 2nd, Sanford CK, et al. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med 2011; 12 Suppl 2:S77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smart R, Pardo B, Davis CS. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction 2021; 116:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JL, Johnson S, Cruz R, et al. Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment. J Gen Intern Med 2021; 36:3810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weicker SA, Speed KA, Hyshka E, et al. Emergency department care for patients who use opioids during the COVID-19 pandemic. CJEM 2022; 24:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serdarevic M, Cvitanovich M, MacDonald BR, et al. Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder. Ann Emerg Med 2023; 82:694.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 300 Version 60.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140178" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140178" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140178" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140178" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25587948" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Trends in opioid analgesic abuse and mortality in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15189164" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Opioid receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707003" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2443865" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34637841" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Treatment of overdose in the synthetic opioid era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34637841" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Treatment of overdose in the synthetic opioid era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36826742" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : New Synthetic Opioids: Clinical Considerations and Dangers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567715" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Opioid metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8968655" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pharmacokinetics of opioids in renal dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8997759" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Fatal heroin 'overdose': a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32271389" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24189594" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21834754" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Drug-related death following release from prison: a brief review of the literature with recommendations for practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6230953" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparison of four opioid analgesics as supplements to nitrous oxide anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1996818" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The empiric use of naloxone in patients with altered mental status: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6839633" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Role of histamine in the hemodynamic and plasma catecholamine responses to morphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26810758" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Noninvasive End Tidal CO2 Is Unhelpful in the Prediction of Complications in Deliberate Drug Poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29562161" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acute Amnestic Syndrome Associated with Fentanyl Overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25817442" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Loperamide toxicokinetics: serum concentrations in the overdose setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25645123" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ventricular tachycardia associated with high-dose chronic loperamide use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27022002" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Not your regular high: cardiac dysrhythmias caused by loperamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27823872" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Epidemiologic Trends in Loperamide Abuse and Misuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27140747" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Loperamide Abuse Associated With Cardiac Dysrhythmia and Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28501383" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Intentional Misuse and Abuse of Loperamide: A New Look at a Drug with "Low Abuse Potential".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24438862" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Racial susceptibility for QT prolongation in acute drug overdoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35552367" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Notes from the Field: Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths - 23 States and the District of Columbia, 2019-2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2802276" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Value of rapid screening for acetaminophen in all patients with intentional drug overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25345436" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cardiac conduction disturbance after loperamide abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12820821" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23023890" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Oxycodone overdose causes naloxone responsive coma and QT prolongation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4037279" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Naloxone in cardiorespiratory arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1559363" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Role of a prehospital medical system in reducing heroin-related deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2311152" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8699555" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32401548" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18641540" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3963538" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A dosing nomogram for continuous infusion intravenous naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32005608" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Opioid Withdrawal Precipitated by Long-Acting Antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32005608" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Opioid Withdrawal Precipitated by Long-Acting Antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30644628" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5129541" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5129541" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4554884" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Methadone-induced pulmonary edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28755998" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Loperamide-Induced Torsades de Pointes: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31684751" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Loperamide toxicity: recommendations for patient monitoring and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31684751" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Loperamide toxicity: recommendations for patient monitoring and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28159815" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17881416" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17881416" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28349617" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29049275" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Notes from the Field: Counterfeit Percocet-Related Overdose Cluster - Georgia, June 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27560775" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12493578" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A new series of 13 buprenorphine-related deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16809994" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Naloxone reversal of buprenorphine-induced respiratory depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189341" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20921918" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35708103" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30199635" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34233349" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35169852" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Isotonitazene, a novel psychoactive substance opioid, detected in two cases following a local surge in opioid overdoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35169852" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Isotonitazene, a novel psychoactive substance opioid, detected in two cases following a local surge in opioid overdoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37642962" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36763346" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Acute metonitazene poisoning reversed by naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22468632" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : "Krokodil":revival of an old drug with new problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23726898" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Breaking worse: the emergence of krokodil and excessive injuries among people who inject drugs in Eurasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5222195" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Deaths from narcotism in New York City. Incidence, circumstances, and postmortem findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18501476" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A descriptive study of an outbreak of clenbuterol-containing heroin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11185966" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A descriptive study of an epidemic of poisoning caused by heroin adulterated with scopolamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27322591" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Fatal Fentanyl: One Pill Can Kill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30961922" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27849133" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Do heroin overdose patients require observation after receiving naloxone?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29530654" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Safety of a Brief Emergency Department Observation Protocol for Patients With Presumed Fentanyl Overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31229387" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29913516" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919527" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28815789" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Cost-effectiveness of emergency department-initiated treatment for opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35752520" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Models for Implementing Emergency Department-Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35752520" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Models for Implementing Emergency Department-Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34922776" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Sustained Implementation of a Multicomponent Strategy to Increase Emergency Department-Initiated Interventions for Opioid Use Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37017967" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37140493" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38110219" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21310583" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16956873" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8034388" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Nasal administration of naloxone is as effective as the intravenous route in opiate addicts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25316516" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Expanding access to naloxone in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21668761" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Project Lazarus: community-based overdose prevention in rural North Carolina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32533570" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34159545" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34817838" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Emergency department care for patients who use opioids during the COVID-19 pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37542490" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
